Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mopidamol

A derivative of dipyridamole that is a phosphodiesterase inhibitor, with potential antiplatelet activity. Mopidamol inhibits the hydrolysis of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), by cyclic nucleotide phosphodiesterases; thus, cAMP- and cGMP-dependent processes are potentiated. This leads to the induction of prostacyclin synthesis, the inhibition of thromboxane B2 synthesis and prevention of platelet activation and aggregation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Rapenton
Code name:RA-233
Chemical structure:2,2',2",2"'-[(4-piperidinopyrimido[5,4-d-]pyrimidine-2,6-diyl)dinitrilo]tetraethanol
2,2',2",2"'-[[4-(1-piperidinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol
2,6-bis(diethanolamino)-4-piperidino-pyrimido[5,4-d]pyrimidine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search